Bis-maltolato-oxovanadium

Orvig et al. (522) have shown that the orally active bis(maltolato) oxovanadium(IV) complex 106 (BMOV) is 3 times more effective in... 

For vanadium(IV), the normal form is VOL2. The EPR spectrum of bis-maltolato-oxovanadium(IV), VO(malt)2, sometimes known as... 

The binding of the insulin-enhancing compound bis(maltolato)oxovanadium (IV) (BMOV) to transferrin and albumin has been studied using EPR and compared to the binding of V0S04 with these proteins [28,29], Both proteins could be impor-... 

Yuen, V.G., E. Vera, M.L. Battell, W.M. Li, and J.H. McNeill. 1999. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Diabetes Res. Clin. Pract. 43 9-19. 

Wasan, K.M., V. Risovic, V.G. Yuen, A. Hicke, and J.H. McNeill. 2004. Effects of three and eight weeks oral administration of bis(maltolato)oxovanadium(IV) on plasma homocysteine and cysteine levels in streptozotocin-induced diabetic rats. Exp. Clin. Cardiol. 9 125-129. 

The inhibition of PTPs by vanadate is of particular interest since this mode of action is supposed to be the primary effect exerted by vanadium applied as an insulin-mimetic agent (see 5.1.1.5). The vanadate-inhibited PTP-IB VIII in Figure 5.19, the structure of which was revealed both by single-crystal X-ray diffraction and two-dimensional H- N NMR spectroscopy, was prepared by treating the phosphatase with either vanadyl sulfate or bis(maltolato)oxovanadium(lV) (BMOV) (7a in Figure 5.2). Irrespective of the nature of the intrinsically applied vanadium species, the same compound with incorporated vanadate(V) was obtained, nicely demonstrating that the active species is vanadate(V), formed by elimination of the ligands and oxidation of to V. In vivo studies further showed that intracellular PTP-IB from rat heart tissue was actively inhibited, and autophosphorylation of the insulin receptor concomitantly enhanced. 

Mohammad A, Wang J and McNeill JH (2002b) Bis(maltolato)oxovanadium(IV) inhibits the activity of FTP IB in Zucker rat skeletal muscle in vivo. Mol Cell Biochem 229 125-128. 

R520 P. W. Winter, A. Al-Qatati, A. L. Wolf-Ringwall, S. Schoeberl, P. B. Chatterjee, B. G. Barisas, D. A. Roess and D. C. Crans, The Anti-Diabetic Bis(maltolato)oxovanadium(iv) Decreases Lipid Order while Increasing Insulin Receptor Localization in Membrane Microdomains , Dalton Trans., [online computer file], 2012, 41, 6419. 

Scheme 5.8 Insulin-mimetic vanadium complexes. In the peroxovanadate complex, L = bipyridine (bipy), oxalate (ox), phenanthroline (phen) and picolinate (pic). BMOV represents bis(maltolato)oxovanadium(IV).

A, adenosine 5 -AMP, adenosine 5 -monophosphate AMD473, / -[ammine-dichloro(2-methyl pyridine)] platinum(II) cAMP, cyclic adenosine monophosphate BBR3464, [(rra 5 -PtCl(NH3)2)2 A-iraK5-Pt(NH3)2 (NH2(CH2) NH2)2 ] + Ben, benzene BEOV, bis(ethylmaltolato)oxovanadium(IV) Bip, biphenyl bipy, bipyridine BMOV, bis(maltolato) oxovanadium(IV) ... 

McNeill JH, Yuen VG, Hoveyda HR, Orvig C. 1992. Bis(maltolato)oxovanadium(TV) is apotent insulin mimic. J Med Chem 35 1489-1491. 

Yuen VG, Orvig C, McNeill JH. 1995. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(TV) following acute and chronic administration. Can J Physiol Pharmacol 73 55-64. 

Hanson GR, Stm Y, Orvig C. 1996. Characterization of the potent insulin mimetic agent bis(maltolato)oxovanadium(TV) (BMOV) in solution by EPR spectroscopy. Inorg C/iem 35 6507-6512. 

Liboiron BD, Thompson KH, Hanson GR, Lam E, Aebischer N, Orvig C. 2005. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(TV) transport and biotransformation of insulin-enhancing vanadium pharmaceuticals. J Am C/iem Roc 127 5104-5115. 

---